ANN ARBOR — Molecular Imaging Inc., a preclinical oncology contract research organization, announced that as of Saturday, April 16, its name will change to MI Bioresearch, with the tagline “Advancing Your Preclinical Oncology.”
The company will unveil its new branding at the American Association of Cancer Research Annual Meeting April 16-20 in New Orleans.
“Our new name and brand reflect the company’s overall growth, expansion and excellence in providing a wide array of client-relevant preclinical oncology services,” said Tom Ludlam Jr., president and CEO.
Examples of the company’s capabilities will be on display at two poster presentations during AACR. On April 19, Matt Thayer, senior assistant scientist, will present “In Depth Myeloid Cell Characterization in the Murine Syngeneic CT26 Colon Carcinoma Model by 10-color Flow Cytometry.” On April 20, Maryland Franklin, PhD, vice president, scientific development, will present “Evaluation of the Immune Response Following Treatment With Anti-CTLA-4 Antibody, Radiation Therapy, or the Combination in a Murine Model of Breast Cancer.”
Since its founding in 2003, MI has broadened its oncology offerings to in vitro services, including complex flow cytometry; in vivo pharmacology services, including expansion into immuno-oncology; and focal irradiation services. These complement MI’s position in the provision of in vivo imaging services.
“We are much more than an imaging services provider,” Ludlam said. “We work closely with our clients to provide the tools, services and consultative support necessary to reach their next breakthrough in oncology drug discovery and development. Our new branding emphasizes the three areas of excellence our clients recognize with MI: preclinical know-how, pharmacology expertise and data-driven insight.”